Investors could bring a securities fraud class action alleging that statements a biotech executive made about the results of an Alzheimer’s drug’s clinical trials were misleading, the 1st U.S. Circuit Court of Appeals has found.
Alfred W. Sandrock Jr., chief medical officer of defendant Biogen, told investors during a 2020 earnings call that “all data” from ...
Enter your user name and password in the fields above to gain access to the subscriber content on this site.
Your subscription includes one set of login credentials for your exclusive use. Security features have been integrated on this site: If someone signs in with your credentials while you are logged in, the site will automatically close your ongoing login and you will lose access at that time.
If you have questions about your subscription, please contact Scott Ziegler.
If you feel your login credentials are being used by a second party, contact customer service at 877-615-9536 for assistance in changing your password.Already a paid subscriber but not registered for online access yet? For instructions on how to get premium web access, click here.